Psyence Biomedical Ltd. Common Shares
Here’s whether Psyence Biomedical Ltd. Common Shares (PBM) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: above the 50-day MA (medium-term momentum positive); 3-month momentum positive (+81.5%). Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-4.21% over 10 days); RSI 95 — overbought, elevated pullback risk; weak 1-year return of -69.1%; rising volume on a downtrend (distribution, 2.99x avg). Currently 89.9% off its 52-week high. Score: -3/7.
PBM is trading below its 200-day MA ($14.74) — a key warning sign the longer-term trend is under pressure. With an RSI of 94.7, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -69.1% compares to +35.1% for SPY (trailed the market by 104.2%). The current 89.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.